- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Multicentre, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (Oberon)
This study is looking at a new medicine called Tozorakimab for people with COPD. It aims to see if it can reduce severe flare-ups and if it's safe. Participants will be compared to those taking a dummy medicine.
For: Chronic Obstructive Pulmonary Disease (COPD)Czechia · Denmark · Bulgaria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Multicentre, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (TITANIA)
This study is testing a new medicine, Tozorakimab, for people with severe COPD who often have flare-ups. We want to see if it reduces these flare-ups and is safe to use. Some people will get the new medicine, others a dummy medicine (placebo).
For: Chronic Obstructive Pulmonary Disease (COPD)Poland · Germany · Italy - RecruitingPHASE3
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
This study looks at a new medicine called Tozorakimab. We want to see if it can help people in hospital with lung infections who need extra oxygen. The goal is to stop them from getting sicker, like needing a breathing machine, or even dying.
For: Viral Lung Infection and Acute Respiratory FailureUnited States · Argentina · Australia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (PROSPERO)
This study is testing a new medicine called Tozorakimab for people with severe COPD. It aims to see if Tozorakimab can reduce flare-ups and is safe to use long-term, compared to a dummy medicine.
For: Chronic Obstructive Pulmonary Disease (COPD)Sweden · Romania · Spain - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (MIRANDA)
This study is testing a new medicine, tozorakimab, for people with lung disease called COPD. It wants to see if this medicine can help reduce flare-ups of COPD. Some people will get the new medicine, and others will get a dummy medicine, alongside their usual care.
For: Chronic Obstructive Pulmonary Disease (COPD)Greece · Denmark · Netherlands - Active not recruitingPHASE3
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
This study is looking into a new medication called tozorakimab for people with severe COPD who have frequent flare-ups. It aims to see if this treatment can reduce these flare-ups and improve symptoms. Patients will receive either the new medicine or a dummy treatment.
For: Chronic Obstructive Pulmonary Disease (COPD)United States · Argentina · Belgium